Literature DB >> 2155065

The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice.

P M Goddard1, M Jones, L A Pollard, M R Valenti, K R Harrap.   

Abstract

Binary combinations of cisplatin and the 5-HT3 antagonist, BRL 43694, have been used to treat both conventional mice bearing either L1210 leukaemia or ADJ/PC6 plasmacytoma and nude mice xenografted with a human ovarian carcinoma (HX/110). In no case was there evidence for antagonism by the antiemetic of the antitumour properties of cisplatin.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2155065     DOI： 10.1007/BF00686242

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  2 in total

1.  In vivo estimation of size of experimental tumors.

Authors:  S D Morrison
Journal:  J Natl Cancer Inst       Date:  1983-08       Impact factor: 13.506

2.  The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.

Authors:  J Bermudez; E A Boyle; W D Miner; G J Sanger
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640
  2 in total
  2 in total

Review 1.  5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis.

Authors:  M S Aapro
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 2.  A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.

Authors:  Gareth J Sanger; Paul L R Andrews
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.